tradingkey.logo

Evoke Pharma Inc

EVOK
11.000USD
0.000
收盤 12/19, 16:00美東報價延遲15分鐘
18.95M總市值
虧損本益比TTM

Evoke Pharma Inc

11.000
0.000

關於 Evoke Pharma Inc 公司

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.

Evoke Pharma Inc簡介

公司代碼EVOK
公司名稱Evoke Pharma Inc
上市日期Sep 25, 2013
CEOD'Onofrio (Matthew J)
員工數量3
證券類型Ordinary Share
年結日Sep 25
公司地址420 Stevens Avenue
城市SOLANA BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92075
電話18583451494
網址https://evokepharma.com/
公司代碼EVOK
上市日期Sep 25, 2013
CEOD'Onofrio (Matthew J)

Evoke Pharma Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--

收入明細

FY2025Q2
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
United States
3.75M
0.00%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 21 小時前
更新時間: 21 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
National Wealth Management Group, LLC
4.65%
DRW Securities, LLC
1.38%
The Vanguard Group, Inc.
1.09%
其他
74.92%
持股股東
持股股東
佔比
Klein (Roger M.)
9.46%
Bleichroeder LP
8.50%
National Wealth Management Group, LLC
4.65%
DRW Securities, LLC
1.38%
The Vanguard Group, Inc.
1.09%
其他
74.92%
股東類型
持股股東
佔比
Investment Advisor
15.82%
Individual Investor
10.62%
Hedge Fund
9.21%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.02%
其他
63.88%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
25
502.38K
22.98%
--
2025Q3
26
502.38K
25.40%
+260.79K
2025Q2
25
242.44K
26.58%
-10.18K
2025Q1
28
252.99K
24.26%
-109.24K
2024Q4
30
218.46K
24.86%
-81.81K
2024Q3
31
208.32K
29.69%
-54.34K
2024Q2
31
262.66K
432.25%
-959.00
2024Q1
39
263.62K
30.12%
+47.85K
2023Q4
36
5.70K
3.76%
+99.00
2023Q3
40
5.65K
7.83%
+642.00
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Bleichroeder LP
68.75K
4.41%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.71K
0.11%
--
--
Aug 31, 2025
D'Onofrio (Matthew J)
9.82K
0.63%
+1.32K
+15.50%
Mar 24, 2025
Geode Capital Management, L.L.C.
7.86K
0.5%
-19.00
-0.24%
Aug 31, 2025
Kowieski (Mark A.)
4.92K
0.32%
+4.92K
--
Mar 24, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
公告日期
類型
比率
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1

常見問題

Evoke Pharma Inc的前五大股東是誰?

Evoke Pharma Inc的前五大股東如下:
Bleichroeder LP
持有股份:68.75K
佔總股份比例:4.41%。
The Vanguard Group, Inc.
持有股份:1.71K
佔總股份比例:0.11%。
D'Onofrio (Matthew J)
持有股份:9.82K
佔總股份比例:0.63%。
Geode Capital Management, L.L.C.
持有股份:7.86K
佔總股份比例:0.50%。
Kowieski (Mark A.)
持有股份:4.92K
佔總股份比例:0.32%。

Evoke Pharma Inc的前三大股東類型是什麼?

Evoke Pharma Inc 的前三大股東類型分別是:
Klein (Roger M.)
Bleichroeder LP
National Wealth Management Group, LLC

有多少機構持有Evoke Pharma Inc(EVOK)的股份?

截至2025Q4,共有25家機構持有Evoke Pharma Inc的股份,合計持有的股份價值約為502.38K,占公司總股份的22.98% 。與2025Q3相比,機構持股有所增加,增幅為-2.42%。

哪個業務部門對Evoke Pharma Inc的收入貢獻最大?

在FY2025Q2,--業務部門對Evoke Pharma Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI